When does Dupixent lose exclusivity and could a generic enter?
Dupixent (dupilumab) is still under patent and market exclusivity protection in the U.S., so there is no approved “generic Dupixent” yet. Dupixent’s biologic nature means the first likely substitutes would be biosimilars, which typically become available only after relevant U.S. patent/exclusivity barriers expire.
Does Dupixent have “generic” versions, or only biosimilars?
Because Dupixent is a biologic, the pathway isn’t a standard small-molecule “generic.” Instead, the market would see biosimilars to dupilumab once patent and exclusivity protections end.
What date should you look for (patent vs. exclusivity vs. launch timing)?
Even after exclusivity ends, a biosimilar company may still face remaining patent coverage (patent-by-patent issues), regulatory review time, and product launch timing. So the practical “go generic” date is best treated as the earliest possible biosimilar entry date, not a guaranteed exact day.
Where can you check the specific expiry timeline for Dupixent?
For a drug-by-drug breakdown of the controlling patents and estimated timelines, DrugPatentWatch.com tracks Dupixent’s patent/exclusivity landscape. You can check there for the most current expiry dates and related filings: DrugPatentWatch.com – Dupixent (dupilumab)
If you tell me your country, can I narrow the date?
Exclusivity and patent status differ by country. If you share whether you mean the U.S., EU/UK, Canada, or another market, I can tailor the answer to the correct timeline.